Verrica Pharmaceuticals
Presencia
Verrica Pharmaceuticals es una empresa que cotiza bajo el símbolo de cotización VRCA (US).
Ejecutivos
Ver el organigrama con sus 14 ejecutivos principales
Biografías más buscadas en Verrica Pharmaceuticals
- Ted White, Director, President and Chief Executive Officer
- Lawrence Eichenfield, Director
- Sean Stalfort, Director
Crear su alerta
para seguir los movimientos de los ejecutivos en Verrica Pharmaceuticals.
Farmacia
Verrica Pharmaceuticals tiene 1.859 competidores entre los que se incluyen Pfizer (Estados Unidos), Sanofi (Francia) y Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacia
- MedMen has filed for bankruptcy protection (publicado el 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado el 23 de marzo de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado el 19 de marzo de 2024).
Otros contactos sugeridos en el sector Farmacia
Noticias
Últimos comunicados de prensa de Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference - Verrica Pharmaceuticals
- Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma - Verrica Pharmaceuticals
- Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™ - Verrica Pharmaceuticals
- View more press releases Close
Redes sociales sobre Verrica Pharmaceuticals
- Verrica Pharmaceuticals en Wikipedia, Google News y Yahoo Finance
- Verrica Pharmaceuticals en LinkedIn, Twitter y YouTube
Ponerse en contacto
Contactar a través de e-mail con sus ejecutivos Ted White 
Llame a Verrica Pharmaceuticals al +1 484...
